Last updated: February 17, 2026
Overview
NDC 60429-0222 corresponds to Vitrakvi (larotrectinib), a targeted therapy developed by Bayer for TRK fusion-positive solid tumors. Approved by the FDA in 2019, it is indicated for adult and pediatric patients aged 12 years and older. It primarily serves niche oncology markets with increasing adoption driven by companion diagnostic testing.
Market Size and Demand Drivers
-
Patient Population: Limited but expanding; estimates suggest approximately 350-500 patients in the US annually. This is based on the prevalence of TRK gene fusions across various solid tumors.
-
Market Growth: The global oncology drug market size was valued at $214 billion in 2021, with targeted therapies accounting for 50%. Niche therapies like larotrectinib are forecasted to grow at a CAGR of 15–20% over the next five years, driven by increased molecular testing and approval expansion.
-
Testing Infrastructure: The rise of NTRK fusion testing influences the adoption rate, with more hospitals offering next-generation sequencing (NGS) panels.
-
Regulatory Landscape: Expanded indications in Europe and Asia could increase market penetration, but access remains limited compared to standard chemotherapy.
Market Competition
-
Direct competitors: entrectinib (Rozlytrek, Pfizer), which was approved shortly after larotrectinib for similar indications. Both drugs target NTRK gene fusions but differ in side effect profiles and regulatory approvals.
-
Indirect competitors: Chemotherapy and other targeted therapies for specific tumor profiles.
-
Market Share: Larotrectinib holds an estimated 55–60% of the NTRK fusion inhibitor market as of 2023, with entrectinib capturing approximately 40–45%.
Price Points and Revenue Estimates
-
Current Pricing: Wholesale acquisition cost (WAC) for larotrectinib is approximately $16,000 per month per patient (varies by region; exact figures depend on negotiated discounts and insurance coverage).
-
Annual Cost per Patient: Approximately $192,000, assuming continuous therapy.
-
Revenue Potential:
-
With an estimated 400 US patients annually, gross revenue potential is around $77 million.
-
Considering cost-sharing, off-label use, and regional price variances, net revenue may be 10–20% lower.
-
Pricing Trends:
-
Price stabilization expected due to limited supply and regulatory exclusivity, but discounts and rebates could affect net prices.
-
New market entrants or biosimilars could pressure pricing downward over the next 3–5 years.
Regulatory and Pricing Policies
-
US: Price setting is influenced by Medicare, Medicaid, and private insurers. No direct price regulation exists, but negotiation power and formulary decisions affect reimbursement.
-
EU and Asia: Price negotiations are region-specific, often leading to lower prices than US levels. International markets account for approximately 30–40% of potential revenue.
-
Patent and Exclusivity: Patents extend until 2030, maintaining market exclusivity, which supports current pricing.
Future Price Projections
| Year |
Estimated Price per Patient |
Market Size |
Projected Revenue |
| 2023 |
$16,000/month |
400 patients |
$77 million (US only) |
| 2024 |
$15,500/month |
400 patients |
$74 million |
| 2025 |
$15,000/month |
450 patients |
$81 million |
| 2026 |
$14,500/month |
500 patients |
$87 million |
Price erosion of around 3–4% annually is expected, driven by market competition and negotiations.
Summary
Larotrectinib's niche position in a rare oncogenic driver niche results in high per-unit pricing, supporting substantial revenues relative to the patient population. Market growth hinges on testing adoption, expansion into new regions, and competitive dynamics. Price projections assume a gradual decline driven by market competition and payor pressure, with total revenue increasing as patient numbers grow.
Key Takeaways
- Larotrectinib (NDC 60429-0222) targets a rare genetic subset, with patient estimates under 1,000 annually in major markets.
- Current US pricing is approximately $16,000 per month, leading to potential annual revenues near $77 million in the US.
- Competitive pressures from entrectinib and potential biosimilars may reduce prices by 3–4% annually over the next five years.
- Market expansion depends on increased testing for NTRK fusions and regulatory approvals in Europe and Asia.
- Overall, larotrectinib maintains high per-patient pricing supported by its orphan drug status and market exclusivity until 2030.
FAQs
1. How does the small patient population affect larotrectinib's pricing strategy?
The limited patient population allows for high per-unit pricing, justified by the targeted nature of the therapy and the high unmet need in this niche.
2. What factors could lead to a decrease in the drug's price in the future?
Introduction of biosimilars, increased competition from entrectinib, and reimbursement pressures could induce price reductions.
3. Are there regional pricing differences for larotrectinib?
Yes, pricing varies, with US prices higher than those negotiated in Europe and Asia due to differing regulatory and reimbursement environments.
4. How significant is the role of molecular testing in expanding larotrectinib's market?
Very significant. Broader testing increases identified patients, directly impacting market size and revenue.
5. What external factors could impact larotrectinib's market projections?
Regulatory changes, new approvals of competitors, advances in testing technology, and reimbursement policies are critical factors.
References
[1] Bayer. (2022). Larotrectinib (Vitrakvi) prescribing information.
[2] Market Watch. (2022). Oncology targeted therapy market analysis.
[3] IQVIA. (2022). Prescription data and drug pricing reports.
[4] FDA. (2019). Approval notice for larotrectinib.
[5] Global Data. (2022). Oncology drug market forecast.
